Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119)

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 3, 2007, Pages 852-857

  Berk, Lawrence ^a   Berkey, Brian ^b   Rich, Tyvin ^c   Hrushesky, William ^d   Blask, David ^e   Gallagher, Michael ^f   Kudrimoti, Mahesh ^g   McGarry, Ronald C ^h   Suh, John ⁱ   Mehta, Minesh ^j  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WJB Dorn VA Medical Center   (United States)

^e BASSETT RESEARCH INSTITUTE   (United States)

^f Scranton Radiation Medicine Association   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

Brain metastases; Chronobiology; Melatonin; Randomized trial; Survival

Indexed keywords

BRAIN; NEUROLOGY; ONCOLOGY; TOXICITY;

BRAIN METASTASES; CHRONOBIOLOGY; MELATONIN; RANDOMIZED TRIALS;

RADIOTHERAPY;

MELATONIN;

ADULT; AGED; ALLERGY; ANALYTIC METHOD; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONOBIOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING DISORDER; HUMAN; INFECTION; MALE; MINI MENTAL STATE EXAMINATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURSIVE PARTITIONING ANALYSIS; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; VISUAL DISORDER; VOMITING;

EID: 34249326606     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.01.012     Document Type: Article

References (37)

1. Reiter R.J. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr Rev 12 (1991) 151-180
2. Reiter R.J. Melatonin: Multi-faceted messenger to the masses. Lab Med 24 (1994) 436-441
3. Blask D.E., Sauer L.A., and Dauchy R.T. Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2 (2002) 113-132
4. Tan D.X., Manchester L.C., Hardeland R., et al. Melatonin: A hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34 (2003) 75-78
5. Di W.L., Kadva A., Johnston A., and Silman R. Variable bioavailability of oral melatonin. N Engl J Med 336 (1997) 1028-1029
6. Dollins A.B., Zhdanova I.V., Wurtman R.J., Lynch H.J., and Deng M.H. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA 91 (1994) 1824-1828
7. DeMuro R.L., Nafziger A.N., Blask D.E., Menhinick A.M., and Bertino Jr. J.S. The absolute bioavailability of oral melatonin (0091-2700). J Clin Pharmacol 42 (2000) 781-784
8. Akagi T., Ushinohama K., Ikesue S., et al. Chronopharmacology of melatonin in mice to maximize the antitumor effect and minimize the rhythm disturbance effect. J Pharmacol Exp Ther 308 (2004) 378-384
9. Bartsch H., and Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm 52 (1981) 269-279
10. Blask D.E., Barthold H.J., Dauchy R.T., et al. Melatonin radiosensitizes tumors and radioprotects normal tissues: Time-of-day dependency. Am Assoc Cancer Res (2000) Abstract 338
11. Lissoni P., Barni S., Ardizzoia A., Tancini G., Conti A., and Maestroni G. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 73 (1994) 699-701
12. Lissoni P., Meregalli S., Nosetto L., et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53 (1996) 43-46
13. Haus E. Chronobiology of the mammalian response to ionizing radiation. Potential applications in oncology. Chronobiol Int 19 (2002) 77-100
14. Rich T.A., Shelton III C.H., Kirichenko A., and Straume M. Chronomodulated chemotherapy and irradiation: An idea whose time has come?. Chronobiol Int 19 (2002) 191-205
15. Dixon D.O., and Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol 41 (1988) 1209-1213
16. Crum R.M., Anthony J.C., Bassett S.S., and Folstein M.F. Population-based norms for the Mini-Mental State Examination by age and educational level. J Am Med Assoc 269 (1993) 2386-2391
17. Tangalos E.G., Smith G.E., Ivnik R.J., et al. The Mini-Mental State Examination in general medical practice: Clinical utility and acceptance. Mayo Clin Proc 71 (1996) 829-837
18. Barni S., Lissoni P., Cazzaniga M., et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 52 (1995) 243-245
19. Brackowski R., Zubelewicz B., Romanowski W., et al. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 8 (1994) 77-880
20. Cerea G., Vaghi M., Ardizzoia A., et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: A randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 23 (2003) 1951-1954
21. Lissoni P. Is there a role for melatonin in supportive care?. Support Care Cancer 10 (2002) 110-116
22. Lissoni P., Barni S., Ardizzoia A., et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 49 (1992) 336-339
23. Lissoni P., Barni S., Fossati V., et al. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Support Care Cancer 3 (1995) 194-197
24. Lissoni P., Barni S., Mandala M., et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35 (1999) 1688-1692
25. Lissoni P., Barni S., Tancini G., et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs. interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69 (1994) 196-199
26. Lissoni P., Brivio F., Barni S., et al. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: Its efficacy in preventing hypotension. Anticancer Res 10 (1990) 1759-1761
27. Lissoni P., Brivio O., Brivio F., et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res 21 (1996) 239-242
28. Lissoni P., Mandala M., and Brivio F. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin. Eur Urol 38 (2000) 115-118
29. Lissoni P., Meregalli S., Fossati V., et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs. chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 80 (1994) 464-467
30. Lissoni P., Paolorossi F., Ardizzoia A., et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 23 (1997) 15-19
31. Lissoni P., Pittalis S., Ardizzoia A., et al. Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Support Care Cancer (1996) 313-316
32. Lissoni P., Tancini G., Barni S., et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer 5 (1997) 126-129
33. Ghielmini M., Pagani O., de Jong J., et al. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer 80 (1999) 1058-1061
34. Sarma A., Rodriguez M.A., Cabanillas F., et al. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma. J Clin Oncol 22 (2004) 8066
35. Di W.-L., Kadva A., Johnston A., and Silman R. Variable bioavailability of oral melatonin. N Engl J Med 336 (1997) 1028-1029
36. Meyers C.A., and Wefel J.S. The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. J Clin Oncol 21 (2003) 3557-3558
37. Murray K.J., Scott C., Zachariah B., et al. Importance of the Mini-Mental Status Examination in the treatment of patients with brain metastases: A report from the Radiation Therapy Oncology Group protocol 91-04. Int J Radiat Oncol Biol Phys 48 (2000) 59-64